BCL2 positive	Diffuse Large B Cell Lymphoma	BCL2 positive	Diffuse Large B Cell Lymphoma	venetoclax Sensitive: C2 – Inclusion Criteria venetoclax Sensitive : C2	venetoclax Sensitive: C2 – Inclusion Criteria venetoclax Sensitive : C2
BCL2 positive	Estrogen Receptor Positive Breast Cancer	BCL2 positive	Estrogen Receptor Positive Breast Cancer	venetoclax Sensitive: C2 – Inclusion Criteria venetoclax Sensitive : C2	venetoclax Sensitive: C2 – Inclusion Criteria venetoclax Sensitive : C2
BCL2 positive	Diffuse Large B Cell Lymphoma	BCL2 positive	Diffuse Large B Cell Lymphoma	methotrexate Sensitive: C3 – Early Trials methotrexate Sensitive : C3	methotrexate Sensitive: C3 – Early Trials methotrexate Sensitive : C3
BCL2 positive	Diffuse Large B Cell Lymphoma	BCL2 positive	Diffuse Large B Cell Lymphoma	pixantrone Sensitive: C3 – Early Trials pixantrone Sensitive : C3	pixantrone Sensitive: C3 – Early Trials pixantrone Sensitive : C3
BCL2 positive	Diffuse Large B Cell Lymphoma	BCL2 positive	Diffuse Large B Cell Lymphoma	venetoclax + polatuzumab vedotin-piiq Sensitive: C3 – Early Trials venetoclax + polatuzumab vedotin-piiq Sensitive : C3	venetoclax + polatuzumab vedotin-piiq Sensitive: C3 – Early Trials venetoclax + polatuzumab vedotin-piiq Sensitive : C3
BCL2 positive	Diffuse Large B Cell Lymphoma	BCL2 positive	Diffuse Large B Cell Lymphoma	venetoclax + ibrutinib Sensitive: D – Preclinical venetoclax + ibrutinib Sensitive : D	venetoclax + ibrutinib Sensitive: D – Preclinical venetoclax + ibrutinib Sensitive : D
BCL2 positive	Diffuse Large B Cell Lymphoma	BCL2 positive	Diffuse Large B Cell Lymphoma	venetoclax + fostamatinib Sensitive: D – Preclinical venetoclax + fostamatinib Sensitive : D	venetoclax + fostamatinib Sensitive: D – Preclinical venetoclax + fostamatinib Sensitive : D

BCL2 positive

Associations